Differences

This shows you the differences between two versions of the page.

--- accelerating_covid-19_therapeutic_interventions_and_vaccines [2022/04/02 19:56]
liam created
+++ accelerating_covid-19_therapeutic_interventions_and_vaccines [2023/07/02 20:47] (current)
liam
@@ Line 1: / Line 1: @@
+====== Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) ======
-=== ACTIV Executive Committee ===
+{{ ::29dce7bcceddea25d429490fda87008d.png?200|}}
+On April 17, 2020, the [[National Institutes of Health]] (NIH) announced the [[Accelerating COVID-19 Therapeutic Interventions and Vaccines]] (ACTIV) [[public-private partnership]] to develop a coordinated research strategy for prioritizing and speeding up development of [[COVID-19 vaccines]] and [[pharmaceutical products]].((//ACTIV.// National Institutes of Health (NIH). Retrieved April 1, 2022, from https://archive.ph/8eMTV))
+ACTIV is a collaboration with the [[Foundation for the National Institutes of Health]] (FNIH), [[Biomedical Advanced Research and Development Authority]] (BARDA), [[center for disease control and prevention|Centers for Disease Control and Prevention]] (CDC), the U.S. [[Food and Drug Administration]] (FDA), the [[US Department of Defense]] (DOD), the [[Department of Veterans Affairs]] (VA), [[Countermeasures Acceleration Group]] (formerly [[Operation Warp Speed]]), and the [[European Medicines Agency]] (EMA).
+===== Membership =====
+==== ACTIV Executive Committee ====
 The ACTIV Executive Committee is made up of representatives from various agencies of the U.S. government and [[pharmaceutical companies]].((//ACTIV Public-Private Partnership.// (2022). National Institutes of Health. https://web.archive.org/web/20220402051949/https://www.nih.gov/sites/default/files/research-training/initiatives/activ/activ-org-chart_3.2.22.pdf))
@@ Line 15: / Line 24: @@
 | [[Janet Woodcock]]  | [[Food and Drug Administration]] (FDA)  | Member  |
-=== Preclinical Working Group ===
+==== Preclinical Working Group ====
 ^ Name  ^ Organization  ^ Role  ^
@@ Line 25: / Line 34: @@
 | [[Marc Charette]]  | [[National Heart, Lung, and Blood Institute]]  | Program Director; Division of Cardiovascular Diseases  |
 | [[Tomas Cihlar]]  | [[pharmaceutical_companies:Gilead Sciences]]  | Vice President and Head of Virology  |
-| [[Christine Colvis]]  | [[National Center for Advancing Translational Sciences]]  | Director, Drug Development Partnership Programs]]  |
+| [[Christine Colvis]]  | [[National Center for Advancing Translational Sciences]]  | Director, Drug Development Partnership Programs  |
 | [[Michael Diamond]]  | [[Washington University School of Medicine in St. Louis]]  | The Herbert S. Gasser Professor, Departments of Medicine, Molecular Microbiology, Pathology & Immunology  |
 | [[Ken Duncan]]  | [[Bill & Melinda Gates Foundation]]  | Deputy Director, Discovery – Therapeutics  |